[Clotting factor concentrates].
Topics of this survey are the indications and use of plasma-derived and recombinant coagulation factor concentrates. These substitution therapies need to be handled carefully by weighing up their effectiveness against the long and short term side effects in the individual patient.
Barthels
M
M
Abteilung Hämatologie, Hämostaseologie und Onkologie, Medizinische Hochschule Hannover. mbarthels.hannover@gmx.de
Oldenburg
J
J
D000925:Anticoagulants / Q000627:therapeutic use; D001779:Blood Coagulation Factors / Q000009:adverse effects / Q000302:isolation & purification / Q000627:therapeutic use*; D005169:Factor VIII / Q000627:therapeutic use; D006467:Hemophilia A / Q000188:drug therapy; D006801:Humans; D011516:Prothrombin / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D018805:Sepsis / Q000188:drug therapy
D000925:Anticoagulants; D001779:Blood Coagulation Factors; D011994:Recombinant Proteins; D011516:Prothrombin; D005169:Factor VIII